Your browser doesn't support javascript.
loading
Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM.
Lanz, Tobias V; Brewer, R Camille; Ho, Peggy P; Moon, Jae-Seung; Jude, Kevin M; Fernandez, Daniel; Fernandes, Ricardo A; Gomez, Alejandro M; Nadj, Gabriel-Stefan; Bartley, Christopher M; Schubert, Ryan D; Hawes, Isobel A; Vazquez, Sara E; Iyer, Manasi; Zuchero, J Bradley; Teegen, Bianca; Dunn, Jeffrey E; Lock, Christopher B; Kipp, Lucas B; Cotham, Victoria C; Ueberheide, Beatrix M; Aftab, Blake T; Anderson, Mark S; DeRisi, Joseph L; Wilson, Michael R; Bashford-Rogers, Rachael J M; Platten, Michael; Garcia, K Christopher; Steinman, Lawrence; Robinson, William H.
Afiliación
  • Lanz TV; Division of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
  • Brewer RC; Department of Neurology, Mannheim Center for Translational Neurosciences (MCTN), Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
  • Ho PP; Department of Neurology and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.
  • Moon JS; The Geriatric Research, Education, and Clinical Center (GRECC), VA Palo Alto Health Care System, Palo Alto, CA, USA.
  • Jude KM; Division of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
  • Fernandez D; The Geriatric Research, Education, and Clinical Center (GRECC), VA Palo Alto Health Care System, Palo Alto, CA, USA.
  • Fernandes RA; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Beckman Center for Molecular Medicine, Stanford, CA, USA.
  • Gomez AM; Division of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
  • Nadj GS; The Geriatric Research, Education, and Clinical Center (GRECC), VA Palo Alto Health Care System, Palo Alto, CA, USA.
  • Bartley CM; Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Beckman Center for Molecular Medicine, Stanford, CA, USA.
  • Schubert RD; Macromolecular Structure Knowledge Center, Stanford ChEM-H Institute, Stanford, CA, USA.
  • Hawes IA; Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Beckman Center for Molecular Medicine, Stanford, CA, USA.
  • Vazquez SE; Division of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
  • Iyer M; The Geriatric Research, Education, and Clinical Center (GRECC), VA Palo Alto Health Care System, Palo Alto, CA, USA.
  • Zuchero JB; Division of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
  • Teegen B; The Geriatric Research, Education, and Clinical Center (GRECC), VA Palo Alto Health Care System, Palo Alto, CA, USA.
  • Dunn JE; Weill Institute for Neurosciences, Department of Psychiatry and Behavioral Sciences, University of California San Francisco, San Francisco, CA, USA.
  • Lock CB; Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
  • Kipp LB; Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
  • Cotham VC; Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA, USA.
  • Ueberheide BM; Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA.
  • Aftab BT; Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA.
  • Anderson MS; Institute of Experimental Immunology, Euroimmun AG, Lubeck, Germany.
  • DeRisi JL; Division of Neuroimmunology, Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.
  • Wilson MR; Division of Neuroimmunology, Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.
  • Bashford-Rogers RJM; Division of Neuroimmunology, Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.
  • Platten M; Department of Biochemistry and Molecular Pharmacology, NYU Perlmutter Cancer Center, NYU School of Medicine, New York, NY, USA.
  • Garcia KC; NYU Langone Health Proteomics Laboratory, Division of Advanced Research Technologies, NYU School of Medicine, New York, NY, USA.
  • Steinman L; Department of Biochemistry and Molecular Pharmacology, NYU Perlmutter Cancer Center, NYU School of Medicine, New York, NY, USA.
  • Robinson WH; NYU Langone Health Proteomics Laboratory, Division of Advanced Research Technologies, NYU School of Medicine, New York, NY, USA.
Nature ; 603(7900): 321-327, 2022 03.
Article en En | MEDLINE | ID: mdl-35073561
ABSTRACT
Multiple sclerosis (MS) is a heterogenous autoimmune disease in which autoreactive lymphocytes attack the myelin sheath of the central nervous system. B lymphocytes in the cerebrospinal fluid (CSF) of patients with MS contribute to inflammation and secrete oligoclonal immunoglobulins1,2. Epstein-Barr virus (EBV) infection has been epidemiologically linked to MS, but its pathological role remains unclear3. Here we demonstrate high-affinity molecular mimicry between the EBV transcription factor EBV nuclear antigen 1 (EBNA1) and the central nervous system protein glial cell adhesion molecule (GlialCAM) and provide structural and in vivo functional evidence for its relevance. A cross-reactive CSF-derived antibody was initially identified by single-cell sequencing of the paired-chain B cell repertoire of MS blood and CSF, followed by protein microarray-based testing of recombinantly expressed CSF-derived antibodies against MS-associated viruses. Sequence analysis, affinity measurements and the crystal structure of the EBNA1-peptide epitope in complex with the autoreactive Fab fragment enabled tracking of the development of the naive EBNA1-restricted antibody to a mature EBNA1-GlialCAM cross-reactive antibody. Molecular mimicry is facilitated by a post-translational modification of GlialCAM. EBNA1 immunization exacerbates disease in a mouse model of MS, and anti-EBNA1 and anti-GlialCAM antibodies are prevalent in patients with MS. Our results provide a mechanistic link for the association between MS and EBV and could guide the development of new MS therapies.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Infecciones por Virus de Epstein-Barr / Esclerosis Múltiple Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Nature Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Infecciones por Virus de Epstein-Barr / Esclerosis Múltiple Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Nature Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos